ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
AC Immune SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026
$2.44+0.04 (+1.88%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2014 to 2025
Operating margin
-1940.1%−1543.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -86.9% | -3.2% | -25.4% | -21.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 15.61 | 16.53 | 1.02 | |
| Interest coverage | -1493.7× | -332.9× | -362.9× | |
| Capex to revenue | 3.9% | 11.1% | 25.2% | |
| Diluted shares | 50M | 72M | 101M |
Where the cash went
Fiscal 2021 to 2025, five years combined
AC Immune generated CHF 334.77M from operations and spent CHF 6.15M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
CHF 334.77M
Used
CHF 6.15M
Capital expenditureCHF 6.15M100%DividendsCHF 00%Share buybacksCHF 00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 4 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-CHF 69.26M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-CHF 69.26M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.71 → 1.02
- No dilutionShare count did not rise100M → 101M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.15 → 0.02